Anaerobic Bacterial Spore Therapeutics and their Manufacture

“肠道微生物群是一种具有药理活性的组织，控制着感染、炎症、受体信号、激素分泌和中枢神经系统信号。这些事件对患者的健康和福祉有重大影响（《自然特别评论》，2012年6月）。肠道微生物组在健康和疾病中的重要性现已得到广泛认识，导致基于活微生物的新疗法的研究、开发和制药投资激增，这些疗法可以治疗慢性肠道相关疾病。梭状芽胞杆菌是人类大肠中最常见的一类微生物。CHAIN Biotech利用其在这些细菌方面的独特专业知识，开发了一种治疗炎症性肠病的新型活生物疗法。该产品已在临床前试验中得到验证，我们现在正在寻找能够生产用于临床试验的孢子的制造合作伙伴。英国没有这样的设施，该项目旨在解决这一瓶颈。更具体地说，合作伙伴将确定在东南部为CHAIN和其他中小型微生物组和生物技术公司建造定制孢子制造工厂的成本和经济可行性。”

"The gut microbiome is a pharmacologically active tissue controlling infection, inflammation, receptor signalling, hormone secretion and central nervous system signalling. These events have significant impacts on patient health and wellbeing (Nature Special Review, June 2012). The importance of the gut microbiome in both health and disease is now widely recognised resulting in an explosion in research, development and pharma investment in new therapeutics, based on live microbes, that can treat chronic gut related diseases.Clostridia are the most prevalent class of microbes in the human large intestine. CHAIN Biotech capitalises on its unique expertise with these bacteria to develop a novel live biotherapeutic for treating inflammatory bowel disease. This product has been validated in pre-clinical tests and we now seek a manufacturing partner that can produce spores for clinical trials. No such facility exists in the UK and this project seeks to address this bottleneck. More specifically, the partners will determine the costs and economic feasibility to build a bespoke spore manufacturing plant in the South East for CHAIN and other SME microbiome and biotech companies."